Niagen Bioscience - Public Comps and Valuation Multiples

Niagen Bioscience Overview

About Niagen Bioscience

Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.

Founded

2000

HQ

Employees

104

Website

niagenbioscience.com

Sectors

Nutraceuticals & Cosmeceuticals

Financials

LTM Revenue $122M

LTM EBITDA $15.4M

EV

$524M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Niagen Bioscience Financials

As of September 2025, Niagen Bioscience reported last 12-month revenue of $122M and EBITDA of $15.4M.

In the same period, Niagen Bioscience generated $77.2M in LTM gross profit and $11.7M in net income.

See Niagen Bioscience valuation multiples based on analyst estimates

Niagen Bioscience P&L

In the most recent fiscal year, Niagen Bioscience reported revenue of $99.6M and EBITDA of $9.2M.

Niagen Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Niagen Bioscience valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$122M	XXX	$99.6M	XXX	XXX	XXX
Gross Profit	$77.2M	XXX	$61.6M	XXX	XXX	XXX
Gross Margin	63%	XXX	62%	XXX	XXX	XXX
EBITDA	$15.4M	XXX	$9.2M	XXX	XXX	XXX
EBITDA Margin	13%	XXX	9%	XXX	XXX	XXX
EBIT	$10.5M	XXX	$7.7M	XXX	XXX	XXX
EBIT Margin	9%	XXX	8%	XXX	XXX	XXX
Net Profit	$11.7M	XXX	$8.6M	XXX	XXX	XXX
Net Margin	10%	XXX	9%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Niagen Bioscience including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $122M. EBITDA for the last twelve months was $15.4M. In the most recent fiscal year, Niagen Bioscience achieved $99.6M in revenue and $9.2M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$122M	Analyst estimates available to subscribers	$99.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$77.2M	Analyst estimates available to subscribers	$61.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	63.4% gross margin	Analyst estimates available to subscribers	61.8% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$15.4M	Analyst estimates available to subscribers	$9.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	12.7% EBITDA margin	Analyst estimates available to subscribers	9.2% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$10.5M	Analyst estimates available to subscribers	$7.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	8.6% EBIT margin	Analyst estimates available to subscribers	7.8% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$11.7M	Analyst estimates available to subscribers	$8.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	9.6% net profit margin	Analyst estimates available to subscribers	8.6% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Niagen Bioscience

This financial data table provides comprehensive performance metrics for Niagen Bioscience, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Niagen Bioscience generated $122M in revenue over the last twelve months.
The company achieved $15.4M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $77.2M.
Net income over the last twelve months reached $11.7M.

Fiscal Year Performance

In the most recent fiscal year, Niagen Bioscience reported $99.6M in total revenue.
Fiscal year EBITDA was $9.2M.
The company maintained a gross profit margin of 61.8% in the most recent fiscal year.
EBITDA margin for the fiscal year was 9.2%.
Net profit margin reached 8.6% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Niagen Bioscience. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Niagen Bioscience Stock Performance

Niagen Bioscience has current market cap of $581M, and EV of $524M.

Market Cap Evolution

Niagen Bioscience Stock Data

As of October 30, 2025, Niagen Bioscience's stock price is $7.

See Niagen Bioscience trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$524M	$581M	XXX	XXX	XXX	XXX	$0.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Niagen Bioscience Valuation Multiples

Niagen Bioscience's trades at 5.3x EV/Revenue multiple, and 56.9x EV/EBITDA.

See valuation multiples for Niagen Bioscience and 15K+ public comps

Niagen Bioscience Financial Valuation Multiples

As of October 30, 2025, Niagen Bioscience has market cap of $581M and EV of $524M.

Equity research analysts estimate Niagen Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Niagen Bioscience has a P/E ratio of 49.6x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$581M	XXX	$581M	XXX	XXX	XXX
EV (current)	$524M	XXX	$524M	XXX	XXX	XXX
EV/Revenue	4.3x	XXX	5.3x	XXX	XXX	XXX
EV/EBITDA	34.0x	XXX	56.9x	XXX	XXX	XXX
EV/EBIT	49.9x	XXX	67.8x	XXX	XXX	XXX
EV/Gross Profit	6.8x	XXX	n/a	XXX	XXX	XXX
P/E	49.6x	XXX	68.0x	XXX	XXX	XXX
EV/FCF	38.6x	XXX	43.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Niagen Bioscience Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Niagen Bioscience Margins & Growth Rates

Niagen Bioscience's last 12 month revenue growth is 21%

Niagen Bioscience's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.5M for the same period.

Niagen Bioscience's rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Niagen Bioscience's rule of X is 66% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Niagen Bioscience and other 15K+ public comps

Niagen Bioscience Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	21%	XXX	24%	XXX	XXX	XXX
EBITDA Margin	13%	XXX	9%	XXX	XXX	XXX
EBITDA Growth	49%	XXX	n/a	XXX	XXX	XXX
Rule of 40	17%	XXX	31%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	66%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$1.0M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.5M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	30%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	6%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	54%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial